Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
1. A double stranded nucleic acid (dsNA) for reducing expression of α-1 antitrypsin mRNA comprising first and second nucleic acid strands that form a duplex region of 21 base pairs, wherein each of said first and second nucleic acid strands has a nucleotide sequence consisting of 21 nucleotides and each of said first and second strands comprises one or more modified nucleotides, wherein the nucleotide sequence of the first nucleic acid strand consists of SEQ ID NO: 1908, and wherein said second strand is 100% complementary to SEQ ID NO: 1908.
2. The dsNA of claim 1 , wherein said one or more modified nucleotides is selected from: a 2′-O-methyl nucleotide; a 2′-fluoro nucleotide, and a 2′-O-methyl nucleotide and a 2′-fluoro nucleotide.
3. The dsNA of claim 1 , wherein said first or said second nucleic acid strand comprises one or more phosphorothioate linkages, or each of said first and second nucleic acid strands comprise one or more phosphorothioate linkages.
4. The dsNA of claim 3 , wherein each of said first and second nucleic acid strands comprises a 3′ terminus, and wherein said first nucleic acid strand comprises a phosphorothioate linkage at said 3′ terminus or said second nucleic acid strand comprises a phosphorothioate linkage at said 3′-terminus or each of said first and second nucleic acid strands comprises a phosphorothioate linkage at said a 3′-terminus.
5. The dsNA of claim 1 , further comprising a targeting ligand attached to said first nucleic acid strand, said second nucleic acid strand, or both first and second nucleic acid strands.
6. The dsNA of claim 5 , wherein said targeting ligand comprises a GalNAc moiety or a tri-antennary GalNAc moiety.
7. The dsNA of claim 1 , wherein said first or second nucleic acid strand comprises one or more inverted abasic residues or each of said first and second nucleic acid strands comprises one or more inverted abasic residues.
8. A formulation comprising the dsNA of claim 1 , wherein said dsNA is present in an amount effective to reduce target α-1 antitrypsin mRNA levels by at least 80-90% when said dsNA is introduced into a cell.
9. The dsNA of claim 1 , wherein said first and second nucleic acid strands are separate nucleic acid molecules.
10. The dsNA of claim 1 , wherein said dsNA is a short interfering RNA (siRNA).
11. The dsNA of claim 1 , wherein each of said 21 nucleotides of each of said first and second nucleic acid strands is a modified nucleotide.
12. The dsNA of claim 9 , wherein each of said 21 nucleotides of each of said first and second nucleic acid strands is a modified nucleotide.
13. The dsNA of claim 1 , wherein said first and second nucleic acid strands each comprise one or more modification patterns.
14. The dsNA of claim 12 , wherein said modified nucleotide is a 2′-O-methyl nucleotide or a 2′-fluoro nucleotide.
15. The dsNA of claim 14 , wherein said first or said second nucleic strand comprises one or more phosphorothioate linkages, or each of said first and second nucleic acid strands comprise one or more phosphorothioate linkages.
16. The dsNA of claim 15 , wherein each of said first and second nucleic acid strands comprises a 3′ terminus, and wherein said first nucleic acid strand comprises a phosphorothioate linkage at said 3′ terminus or said second nucleic acid strand comprises a phosphorothioate linkage at said 3′-terminus or each of said first and second nucleic acid strands comprises a phosphorothioate linkage at said a 3′-terminus.
17. The dsNA of claim 16 , further comprising a targeting ligand attached to said first nucleic acid strand, said second nucleic acid strand, or both said first and second nucleic acid strands.
18. The dsNA of claim 17 , wherein said targeting ligand comprises a GalNAc moiety or a tri-antennary GalNAc moiety.
19. The dsNA of claim 18 , wherein said first or second nucleic acid strand comprises one or more inverted abasic residues or each of said first and second nucleic acid strands comprises one or more inverted abasic residues.
20. The dsNA of claim 9 , further comprising a targeting ligand attached to said first nucleic acid strand, said second nucleic acid strand, or both said first and second nucleic acid strands.
21. The dsNA of claim 20 , wherein said targeting ligand comprises a GalNAc moiety or a tri-antennary GalNAc moiety.
22. The dsNA of claim 9 , wherein said first or second nucleic acid strand comprises one or more inverted abasic residues or each of said first and second nucleic acid strands comprises one or more inverted abasic residues.
23. The dsNA of claim 9 , wherein said first or said second nucleic strand comprises one or more phosphorothioate linkages, or each of said first and second nucleic acid strands comprise one or more phosphorothioate linkages.
24. The dsNA of claim 23 , wherein each of said first and second nucleic acid strands comprises a 3′ terminus, and wherein said first nucleic acid strand comprises a phosphorothioate linkage at said 3′ terminus or said second nucleic acid strand comprises a phosphorothioate linkage at said 3′-terminus or each of said first and second nucleic acid strands comprises a phosphorothioate linkage at said a 3′-terminus.
25. The dsNA of claim 21 , wherein said first or second nucleic acid strand comprises one or more inverted abasic residues or each of said first and second nucleic acid strands comprises one or more inverted abasic residues.